New clinical studies show that Bactiguard-coated catheters reduce hospital acquired infections
Two recent clinical studies, both independent and randomized, show that Bactiguard-coated Foley catheters and endotracheal tubes reduce catheter associated urinary tract infections and ventilator associated pneumonia.
The first study was conducted in Spain and included 116 patients catheterized for
2 – 14 days, with a mean of 4 days, during the immediate postoperative period following cardiac surgery. The incidence of catheter associated urinary tract infections was significantly lower (38 percent) for patients with Bactiguard-coated Foley catheters (BIP Foley) compared to patients with standard catheters. An economic evaluation in the publication confirms that using Bactiguard-coated catheters also is a cost-effective alternative to prevent catheter associated urinary tract infections and reduce the number of patient days. The study is published in Enfermeria Intensiva*.
The other study was conducted in Romania and included 100 patients intubated for five days. The study shows a 67 percent lower incidence of ventilator associated pneumonia for patients with Bactiguard-coated endotracheal tubes (BIP ETT), compared to patients with standard ETTs. Significantly less antibiotics was also used for patients using Bactiguard-coated catheters. It was concluded that the use of BIP ETTs is associated with a lower incidence of infections and that they are more cost- effective than standard ETTs. The study was presented as a poster at the European Euroanasthesiology Congress in Berlin in June 2015.**
* Fabrellas H et al; Incidence of urinary tract infections after cardiac surgery: comparative study according to catheterization device. Enferm Intensiva, 21 March 2015. PMID: 25804335, available at http://www.ncbi.nlm.nih.gov/pubmed/25804335
Abstract available in English. Please contact Bactiguard for further information.
** The abstract is available at the Euroanasthesia homepage, page 377:
For further information, please contact:
Susann Remnert, Communication Manager, mobile: +46 709 195 342
Bactiguard is a Swedish medtech company with a mission of preventing healthcare associated infections, reducing the use of antibiotics and saving lives by developing and supplying infection prevention solutions for the healthcare industry. The company’s patented coating prevents healthcare associated infections by reducing bacterial adhesion and growth on medical devices. Bactiguard®-coated urinary catheters are market leading in the US and Japan, and in recent years the company has developed its own product portfolio of catheters for the urinary and respiratory tract and the blood stream. Bactiguard is currently in a strong expansion phase, focused on new markets in the Europe, Middle East, Asia, Latin America and Southern Africa. The company has market presence in some 50 countries and has about 60 employees. Its headquarters is located in Stockholm and production facilities in Sweden and Malaysia. Bactiguard is listed on Nasdaq Stockholm. Read more about Bactiguard at www.bactiguard.com